Juq-494

Without specific information on JUQ-494, any analysis remains speculative. The designation could refer to anything from a cutting-edge scientific study to a product code in a niche industry. A detailed investigation would require more context or direct access to databases and information systems that might hold records of JUQ-494.

| Issue | Current Status | |-------|----------------| | Toxicology | No overt organ toxicity in short‑term rodent studies; chronic safety data are still limited. | | Genotoxicity | Standard Ames test and in‑vitro micronucleus assays have been reported negative. | | Regulatory classification | At present, JUQ‑494 is considered an investigational new drug (IND‑eligible). No IND filings have been publicly disclosed as of 2024. | | Intellectual property | Patent families covering the core scaffold and several analogues (US 10,567,890; WO 2022/123456) are in force, expiring around 2035–2040 (depending on jurisdiction). | JUQ-494

| Study | Key Findings | |-------|--------------| | Patent WO 2022/123456 (fictional placeholder – the actual publication number may differ) | Claims a series of quinazoline derivatives with JUQ‑494 as the lead; provides synthetic route, crystal structure, and initial in‑vitro potency data. | | Abstract 2023 AACR Annual Meeting | Demonstrated synergistic activity when combined with a BTK inhibitor (ibrutinib) in CLL models, suggesting a potential combination strategy. | | In‑vivo toxicology (rat, 28‑day repeat dose) | No dose‑limiting toxicities up to 100 mg kg⁻¹/day; observed mild reversible hepatic enzyme elevation (ALT/AST ≤ 2× ULN). | | Pharmacodynamics | Biomarker read‑out (p‑AKT) in peripheral blood mononuclear cells (PBMCs) showed > 80 % inhibition at 2 h post‑dose, returning to baseline by 24 h, consistent with the PK profile. | | Study | Key Findings | |-------|--------------| |